کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2754289 1149768 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise
ترجمه فارسی عنوان
ایروتینیب به عنوان یک مهار کننده بروتون کیناز در مدیریت لوسمی مزمن لنفوسیتی: عامل جدید با وعده بزرگ
کلمات کلیدی
عامل انتینوپلاستی، آزمایشات بالینی، دارودرمانی، آنتاگونیست ها / مهار کننده های پروتئین تیروزین کیناز، مرور
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیهوشی و پزشکی درد
چکیده انگلیسی

The recent discovery of the role of the B-cell antigen receptor (BCR) signaling pathway in the propagation and maintenance of both normal B-cell function and in B-cell malignancies has highlighted the importance of many protein kinases involved in BCR signal propagation. Considerable research attention has focused on the Bruton tyrosine kinase (BTK) as a potential therapeutic target in B-cell malignancies. Treatment paradigms including ibrutinib, a potent inhibitor of the BTK recently approved by the US Food and Drug Administration, have significantly improved disease outcome among high-risk and relapsed/refractory cases of chronic lymphocytic leukemia. This has provided additional treatment options, especially among the elderly, where improved disease response has been accompanied by more manageable treatment-associated toxicity than commonly found with chemoimmunotherapy. In this review, we provide a synopsis of the current data on the efficacy and clinical utilization of ibrutinib and management of its resistance in the treatment of chronic lymphocytic leukemia.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Lymphoma Myeloma and Leukemia - Volume 16, Issue 2, February 2016, Pages 63–69
نویسندگان
, , , ,